Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer

Oncology Reports

Volumn 31, Issue 5, 2014, Pages 2107-2114

  Mu, Jiasheng ^a,b   Xu, Haineng ^c   Yang, Yu ^c   Huang, Weidan ^c   Xiao, Jing ^d   Li, Maolan ^a,b   Tan, Zhujun ^a,b   Ding, Qichen ^a,b   Zhang, Lin ^a,b   Lu, Jianhua ^a,b   Wu, Xiangsong ^a,b   Liu, Yingbin ^a,b  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^d HENAN NORMAL UNIVERSITY   (China)

Author keywords

Antipsychotic drug; Apoptosis; Caspase; Gastric cancer; In vivo; Mitochondria; Thioridazine

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; LIPOCORTIN 5; THIORIDAZINE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; NEUROLEPTIC AGENT; PEPTIDE CHLOROMETHYL KETONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CANCER; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NUDE MOUSE; STOMACH NEOPLASMS; TUMOR CELL LINE;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIPSYCHOTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; STOMACH NEOPLASMS; THIORIDAZINE;

EID: 84898670691     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3068     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011
3. Kang S, Dong SM, Kim BR, Park MS, Trink B, Byun HJ and Rho SB: Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis 17: 989-997, 2012
4. Strobl JS, Kirkwood KL, Lantz TK, Lewine MA, Peterson VA and Worley JF III: Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine. Cancer Res 50: 5399-5405, 1990
5. Gil-Ad I, Shtaif B, Levkovitz Y, Dayag M, Zeldich E and Weizman A: Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: Clinical relevance and possible application for brain-derived tumors. J Mol Neurosci 22: 189-198, 2004
6. Zhelev Z, Ohba H, Bakalova R, Hadjimitova V, Ishikawa M, Shinohara Y and Baba Y: Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. Cancer Chemother Pharmacol 53: 267-275, 2004
7. Rho SB, Kim BR and Kang S: A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol 120: 121-127, 2011
8. Byun HJ, Lee JH, Kim BR, Kang S, Dong SM, Park MS, Lee SH, Park SH and Rho SB: Anti-angiogenic effects of thioridazine involving the FAK-mTOR pathway. Microvasc Res 84: 227-234, 2012
9. Ramu A, Spanier R, Rahamimoff H and Fuks Z: Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells. Br J Cancer 50: 501-507, 1984
10. Akiyama S, Shiraishi N, Kuratomi Y, Nakagawa M and Kuwano M: Circumvention of multiple-drug resistance in human cancer cells by thioridazine, trifluoperazine, and chlorpromazine. J Natl Cancer Inst 76: 839-844, 1986
11. Castaing M, Loiseau A and Cornish-Bowden A: Synergy between verapamil and other multidrug-resistance modulators in model membranes. J Biosci 32: 737-746, 2007
12. Kamiwatari M, Nagata Y, Kikuchi H, Yoshimura A, Sumizawa T, Shudo N, Sakoda R, Seto K and Akiyama S: Correlation between reversing of multidrug resistance and inhibiting of [3H]azidopine photolabeling of P-glycoprotein by newly synthesized dihydropyridine analogues in a human cell line. Cancer Res 49: 3190-3195, 1989
13. Spengler G, Molnar J, Viveiros M and Amaral L: Thioridazine induces apoptosis of multidrug-resistant mouse lymphoma cells transfected with the human ABCB1 and inhibits the expression of P-glycoprotein. Anticancer Res 31: 4201-4205, 2011
14. Sachlos E, Risueno RM, Laronde S, et al: Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149: 1284-1297, 2012
15. Gil-Ad I, Shtaif B, Levkovitz Y, Nordenberg J, Taler M, Korov I and Weizman A: Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. Oncol Rep 15: 107-112, 2006
16. Efferth T and Volm M: Reversal of doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms. Cancer Lett 70: 197-202, 1993
17. Sutton LP and Rushlow WJ: The dopamine D2 receptor regulates Akt and GSK-3 via Dvl-3. Int J Neuropsychopharmacol 15: 965-979, 2012
18. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, Schultz PG and Reddy VA: The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 106: 268-273, 2009
19. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27: 1006-1020, 2009
20. Gabalec F, Beranek M, Netuka D, Masopust V, Nahlovsky J, Cesak T, Marek J and Cap J: Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas. Pituitary 15: 222-226, 2012
21. Gatto F and Hofland LJ: The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr Relat Cancer 18: R233-R251, 2011
22. Xu HN, Huang WD, Cai Y, et al: HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy. Mol Cancer 10: 133, 2011
23. Ding M, Cao X, Xu HN, et al: Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene. PLoS One 7: E35153, 2012
24. Sheikhpour M, Ahangari G, Sadeghizadeh M and Deezagi A: A novel report of apoptosis in human lung carcinoma cells using selective agonist of D2-like dopamine receptors: A new approach for the treatment of human non-small cell lung cancer. Int J Immunopathol Pharmacol 26: 393-402, 2013
25. Senogles SE: D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69. Anticancer Drugs 18: 801-807, 2007